NO973724L - Medisinske kombinasjoner anvendelige for in vivo eksogen transfeksjon og ekspresjon - Google Patents

Medisinske kombinasjoner anvendelige for in vivo eksogen transfeksjon og ekspresjon

Info

Publication number
NO973724L
NO973724L NO973724A NO973724A NO973724L NO 973724 L NO973724 L NO 973724L NO 973724 A NO973724 A NO 973724A NO 973724 A NO973724 A NO 973724A NO 973724 L NO973724 L NO 973724L
Authority
NO
Norway
Prior art keywords
expression
vivo
combinations useful
medical
transfection
Prior art date
Application number
NO973724A
Other languages
English (en)
Other versions
NO973724D0 (no
NO320072B1 (no
Inventor
Jean-Francois Bach
Lucienne Chatenoud
Hedi Haddada
Martin Lee
Michel Perricaudet
Michelle Webb
Original Assignee
Rhone Poulenc Rorer Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa, Inst Nat Sante Rech Med filed Critical Rhone Poulenc Rorer Sa
Publication of NO973724D0 publication Critical patent/NO973724D0/no
Publication of NO973724L publication Critical patent/NO973724L/no
Publication of NO320072B1 publication Critical patent/NO320072B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO19973724A 1995-02-14 1997-08-13 Medikamentos assosiasjon for anvendelse for eksogene transfeksjoner in vivo og/eller ex vivo. NO320072B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9501662A FR2730411B1 (fr) 1995-02-14 1995-02-14 Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
PCT/FR1996/000218 WO1996025177A1 (fr) 1995-02-14 1996-02-12 Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes

Publications (3)

Publication Number Publication Date
NO973724D0 NO973724D0 (no) 1997-08-13
NO973724L true NO973724L (no) 1997-08-13
NO320072B1 NO320072B1 (no) 2005-10-17

Family

ID=9476106

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19973724A NO320072B1 (no) 1995-02-14 1997-08-13 Medikamentos assosiasjon for anvendelse for eksogene transfeksjoner in vivo og/eller ex vivo.

Country Status (23)

Country Link
US (2) US20030004091A1 (no)
EP (1) EP0809516B1 (no)
JP (1) JPH11500430A (no)
KR (1) KR100402540B1 (no)
AT (1) ATE204481T1 (no)
AU (1) AU717218B2 (no)
BR (1) BR9607310A (no)
CA (1) CA2211039C (no)
CZ (1) CZ258197A3 (no)
DE (1) DE69614668T2 (no)
DK (1) DK0809516T3 (no)
ES (1) ES2163612T3 (no)
FI (1) FI119176B (no)
FR (1) FR2730411B1 (no)
GR (1) GR3036438T3 (no)
HU (1) HU222991B1 (no)
IL (1) IL117116A0 (no)
MX (1) MX9706017A (no)
NO (1) NO320072B1 (no)
PT (1) PT809516E (no)
SK (1) SK282235B6 (no)
WO (1) WO1996025177A1 (no)
ZA (1) ZA961161B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
WO1998008539A1 (en) * 1996-08-26 1998-03-05 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
CA2308017A1 (en) 1997-10-30 1999-05-14 Erik S. Falck-Pedersen A method of inhibiting an immune response to a recombinant vector
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性hivc型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
WO2000074688A1 (en) * 1999-06-08 2000-12-14 The Children's Hospital Of Philadelphia Methods for preventing formation of inhibitory antibodies in the setting of gene therapy
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
IL152450A0 (en) 2000-05-12 2003-05-29 Genzyme Corp COMPOUNDS HAVING TNF-alpha SIGNAL MODULATING ACTIVITY
WO2003004620A2 (en) 2001-07-05 2003-01-16 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7569217B2 (en) * 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
US20030139374A1 (en) * 2001-09-27 2003-07-24 Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. Combined methods for tumor vasculature coagulation and treatment
EP1562571B1 (en) * 2002-11-21 2011-08-17 Genzyme Corporation Combination of a diamide derivative and immunosuppressive agents for inhibiting transplant rejection
ATE493980T1 (de) * 2002-11-21 2011-01-15 Genzyme Corp Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung
EP1725254A4 (en) * 2004-02-04 2008-02-13 Univ Columbia ANTI-CD3 AND ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR THE TREATMENT OF AUTOIMMUNITY
WO2008013918A2 (en) * 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5962694A (en) * 1992-12-31 1994-08-15 Exemplar Corporation Producing cells for transplantation to reduce host rejection and resulting cells
WO1994016080A1 (en) * 1993-01-08 1994-07-21 Exemplar Corporation An in vitro/in vivo method for identifying anti-neoplastic drugs
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus

Also Published As

Publication number Publication date
MX9706017A (es) 1997-11-29
FI119176B (fi) 2008-08-29
FI973323A0 (fi) 1997-08-13
ATE204481T1 (de) 2001-09-15
KR100402540B1 (ko) 2004-05-07
FI973323A (fi) 1997-08-13
HUP9800635A2 (hu) 1998-07-28
DK0809516T3 (da) 2001-12-17
SK110897A3 (en) 1998-01-14
CA2211039C (fr) 2011-12-06
ES2163612T3 (es) 2002-02-01
GR3036438T3 (en) 2001-11-30
NO973724D0 (no) 1997-08-13
KR19980702199A (ko) 1998-07-15
EP0809516B1 (fr) 2001-08-22
NO320072B1 (no) 2005-10-17
SK282235B6 (sk) 2001-12-03
ZA961161B (en) 1996-08-07
EP0809516A1 (fr) 1997-12-03
FR2730411A1 (fr) 1996-08-14
HU222991B1 (hu) 2004-01-28
CA2211039A1 (fr) 1996-08-22
US20030004091A1 (en) 2003-01-02
DE69614668T2 (de) 2002-06-27
CZ258197A3 (en) 1997-11-12
WO1996025177A1 (fr) 1996-08-22
IL117116A0 (en) 1996-06-18
AU4723896A (en) 1996-09-04
PT809516E (pt) 2002-02-28
DE69614668D1 (de) 2001-09-27
US20040265276A1 (en) 2004-12-30
BR9607310A (pt) 1997-11-25
JPH11500430A (ja) 1999-01-12
FR2730411B1 (fr) 1997-03-28
HUP9800635A3 (en) 2000-12-28
AU717218B2 (en) 2000-03-23

Similar Documents

Publication Publication Date Title
NO973724L (no) Medisinske kombinasjoner anvendelige for in vivo eksogen transfeksjon og ekspresjon
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
FI973467A (fi) DNA-molekyylejä, valmistus ja käyttö geeniterapiassa
GR3032744T3 (en) Surface expression of enzyme in gene directed prodrug therapy
ATE323169T1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
DE69819167D1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
FI970768A0 (fi) Kasvainten geeniterapiahoito endoteelisoluspesifisellä, solusyklistä riippuvalla vaikuttavalla aineella
ES2115662T3 (es) Modificacion genetica de celulas endoteliales.
CY1109367T1 (el) Συνθεσεις και μεθοδοι για ενισχυση της παροχης θεραπευτικων παραγοντων σε κυτταρα
IL129445A0 (en) Improvements in or relating to diagnostic/therapeutic agents
MX9606327A (es) Adenovirus que comprende un gen que codifica para un superoxido dismutasa.
IL131014A0 (en) Methods for cultivating cells and propagating viruses
NO974179L (no) Rekombinante viruser som uttrykker lecitin-kolesterol-acyltransferase, og anvendelse derav i genterapi
EE200000102A (et) Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
DK0880594T3 (da) Retroviral vektor og dens anvendelse i genterapi
NO992577D0 (no) Transfeksjonsblanding for anvendelse ved genterapi og som kombinerer en rekombinant virus som inkorporerer en exogen nukleinsyre, med et ikke-viralt, ikke-plasmidisk transfeksjonsmiddel
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees